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SocietyThe introduction of cyclooxygenase-2 (COX-2) selective
inhibitors (coxibs) for the treatment of osteoarthritis (OA),
rheumatoid arthritis, and pain was heralded as a signiﬁcant
advance in the clinical armamentarium. Efﬁcacy equal to
those of the non-selective non-steroidal anti-inﬂammatory
drugs (NSAIDs) associated with a safer toxicity proﬁle,
particularly as it related to gastrointestinal (GI) adverse
events such as peptic ulcer, bleeding, obstruction, and
perforation, led to a high level of enthusiasm with respect to
their routine use. The estimated 16,500 deaths per year
associated with GI bleeds in patients receiving non-
selective NSAIDs, made the switch to coxibs especially
attractive. Coxibs advantages were recognized in guide-
lines published by the American College of Rheumatology,
EULAR (European League Against Rheumatism), and the
American Pain Society recommending their use in arthritis
and pain management.
An increased rate of cardiovascular (CV) events including
acute myocardial infarction (AMI), stroke, and peripheral
vascular thrombotic syndromes was ﬁrst noted in the
VIGOR study associated with the use of rofecoxib 50 mg
daily1. A large study of celecoxib at a dose of 400 mg b.i.d.2
which exhibited no increase in thromboembolic CV adverse
events whether or not patients were using aspirin was
reassuring regarding the question of a negative coxib-
related CV class effect. However, the ﬁnding of increased
CV events associated with rofecoxib 25 mg daily, in
a colorectal adenoma chemoprevention trial (APPROVe)3
(relative risk (RR) 1.92 for thrombotic events vs the placebo
group), apparent only after 18 months of treatment, led to
a voluntary withdrawal of rofecoxib from the world market,
and a concern regarding possible potential for all coxibs to
show a similar CV adverse event proﬁle.
The issue as to whether this represented a class effect for
COX-2 selective inhibitors was reintroduced when an
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trial for colorectal adenoma prevention (APC Trial)4;
a composite CV end-point of death 2.8e3.1 years of
follow-up from CV causes, including AMI, stroke, or heart
failure was reached in 1% of the placebo group, 2.3% of the
celecoxib 200 mg b.i.d. group, and 3.4% of subjects in the
celecoxib 400 mg b.i.d. group. On the basis of these
ﬁndings, the Data and Safety Monitoring Board recommen-
ded early discontinuation of the study. In contrast to this
latter study, however, a similar clinical trial being carried out
for adenoma prevention (PreSAP Trial) revealed no in-
crease in fatal or non-fatal CV events in patients receiving
celecoxib 400 mg/day as compared to placebo. An earlier
unpublished study assessing the efﬁcacy of celecoxib,
200 mg b.i.d., in limiting the progression of Alzheimer’s
Disease was associated with an increase in CV events as
compared to placebo5; interpretation of the ﬁndings was
complicated by imbalances in baseline medical history for
subjects with regard to hypertension (HTN), diabetes and
coronary artery disease; small sample size; small number of
events decreasing robustness of results; and imbalance in
randomization. A 1-year study of lumiracoxib, a new coxib
under investigation, revealed a numerical, but not statisti-
cally signiﬁcant, increase in CV events as compared to
naproxen (hazard ratioZ 1.77 [0.82e3.84], PZ 0.15)6.
Results of the 3-year ADAPT Trial, set up to compare the
efﬁcacy of celecoxib and naproxen in Alzheimer’s pre-
vention, added a confusing and unexpected ﬁnding to the
mix of observations. Subjects taking celecoxib, 200 mg
twice daily, showed no increase in CV or cerebrovascular
events; in contrast, there was a suggestive increase of CV
events associated with sodium naproxen at 220 mg b.i.d.,
the over-the-counter (OTC) dose as compared to those
taking placebo7. In regard to the latter, in controlled trials,
rofecoxib1, lumiracoxib6 and etoricoxib exhibited a RR for
CV events of 1.7e2.38 when compared to full-dose
naproxen as a comparator.
In a similar vein, a CV risk was identiﬁed in patients
receiving parecoxib (the precursor molecule to valdecoxib)
and valdecoxib in two trials utilizing these agents for peri-
operative pain control in patients undergoing coronary-
artery-bypass grafting surgery (CABG)8,9; no increase in
CV events was noted, however, in similar trials in patients
undergoing various non-CV surgical procedures. It is also
noteworthy that all patients in the CABG trials also
received co-treatment with low-dose aspirin. Therefore,5
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studies must take into account the fact that both COX-1
and COX-2 were inhibited in these high risk patients.
Prior observational studies10,11 showed no increase in risk
of AMI related to celecoxib use. An as yet unpublished
epidemiologic study on CV risks with coxibs and NSAIDs
evaluated CV risk factors and NSAID use in a sample size of
over 7 million persons per year enrolled in California
Medicaid12. This study had the advantage of available OTC
aspirin data; no censoring at age 65; long durations of follow-
up with low drop-out rates; and sicker populations than
private-payors. The risk of AMI with celecoxib revealed no
apparent increased risk of AMI at doses of 200 mg/day or
less; valdecoxib also revealed no increased risk. Of interest
was an increased risk of AMI with indomethacin, meloxicam,
and sulindac. It was concluded that, as a class, non-coxib
NSAIDs may increase CV risk; differences existed between
non-coxib NSAIDs with respect to such risk; and that
naproxen was not cardio-protective.
One mechanism whereby coxibs might be associated
with increased CV risk is based on an imbalance between
inhibition of thromboxane and prostacyclin. Coxibs would
shift the trend toward thrombosis by inhibiting prostacyclin,
a thrombosis-inhibiting prostaglandin while, at the same
time, thrombosis-promoting thromboxane was not inhibited.
A second mechanism which might pertain is an increase in
HTN and edema, seen to various degrees both with non-
selective NSAIDs and coxibs. This latter mechanism may
explain observed increases in CV risk seen with non-
selective NSAIDs.
The potential CV thrombotic effects attributed to the coxibs
may be shared by other NSAIDs on a mechanistic basis,
underscoring the complexity of the issue. Effective inhibition
of platelet aggregation requires sustainedO80% inhibition of
platelet COX-1, a level achieved by aspirin and high dose
naproxen. Other NSAIDs, including low doses of ibuprofen
(e.g., Advil), diclofenac, and meloxicam, amongst others do
not achieve this degree of thromboxane inhibition throughout
their dosing interval andmay therefore, like coxibs, also result
in unbalanced thromboxane-prostacyclin inhibition13. This is
important to considerwhenassessing thepotential increased
risk of OTCdoses of NSAIDs (e.g., Aleve as compared to full-
dose naproxen). Of related interest is the observation that
acetaminophen, 500 mg, administered to healthy volunteers
caused a marked reduction of prostacyclin synthesis for
6e8 h without any obvious effect on thromboxane synthesis,
a pattern similar to that described with coxibs14.
The non-selective NSAIDs have not been subjected to
placebo-controlled long-term studies and where evaluated,
non-naproxen NSAIDs did not differ from coxibs in long-term
outcome studies where they served as comparators.
Examples include diclofenac and ibuprofen in the Celecoxib
Long-term Arthritis Safety Study (CLASS), ibuprofen in
Therapeutic Arthritis Research and Gastrointestinal Event
Trial (TARGET), and diclofenac in Etoricoxib DiclofenacGastrointestinal Evaluation (EDGE) (Table I). Therefore, if
the coxibs imparted CV risk in these 1-year studies, they
would have performed no worse than ibuprofen and
diclofenac. Indeed, in aspirin-treated patients studied in
TARGET, the risk of CV events in patients receiving
ibuprofen exceeded that of those who received lumiracoxib.
The TARGET study once again raises the question whether
short-acting NSAIDs, such as ibuprofen, interfere with the
anti-platelet effect of low-dose aspirin. Evenmore perplexing
is the observation that aspirin intake in a study of colorectal
adenoma protection was associated with a dose-related
numerical increase in frequency of AMI and stroke15.
As noted, an important question is the issue as to
whether the ﬁnding of increased CV events observed with
rofecoxib represents a class effect or whether there are
differences in coxibs in their CV risk proﬁle. Differences
between the CV risks associated with coxibs at usual dose
schedules may be the result of the different half-lives and
lower protein-binding; longer half-life and decreased protein-
binding would allow more free drug to be active for a longer
period following administration in a given patient.
Limitations in interpreting the above studies, someofwhich
are contradictory in terms of their ﬁndings, may represent
deﬁciencies inherent to short-term studies; differences in
dosage schedules; and differences in patient populations
who, at baseline, are at varying risks for myocardial events.
Subsequent to a United States Federal Drug Administra-
tion (FDA) review in April 2005, valdecoxib was, at the
request of the FDA, voluntarily withdrawn from the market
due to CV and cutaneous toxicity safety concerns. All
marketed prescription NSAIDs, both non-COX-2 selective
and COX-2 selective, were to require a revision in labeling to
include a boxed warning, highlighting the potential for
increased CV events and GI bleeding. In addition, the FDA
requested manufacturers of non-prescription (over-the-
counter) NSAIDs to include more speciﬁc information on
potential CV and GI risks. In an FDA Executive Summary
Report16, it was deemed reasonable to conclude that there is
a ‘‘class effect’’ for increased CV risk for all NSAIDs pending
the availability of data from long-term controlled clinical trials
more clearly delineating true relationships. Data at this point
did not allow concluding that COX-2 selective drugs
conferred an increased risk over non-selective NSAIDs in
chronic use. This interpretation of available data would serve
to alert physicians and patients that simply switching from
a COX-2 selective agent to a non-selective NSAID does not
mean that the potential for increased risk of serious adverse
CV events has been fully, or even partially, mitigated16.
The main issue is ‘‘where do we go from here’’? NSAIDs
have an increased risk of GI bleeding, perforation, and
obstruction, especially in high risk patients with a history of
past or present ulcer disease. Use of proton-pump inhibitors
may protect the upper GI tract and also is effective on
dyspepsia, but would not be protective for patients with
respect to lower GI bleeds. Coxibs, on the other hand, areTable I
Adverse events profiles in active comparator trials: coxibs vs non-selective NSAIDs
Trial Diagnosis Subjects
(number)
COX-2 NSAIDs comparator CV adverse events:
coxibs vs NSAIDs
CLASS* OA 5968 Celecoxib 400 mg twice daily for up to 15 months Diclofenac 75 mg b.i.d. No CV increase
Ibuprofen 800 mg t.i.d.
TARGET* OA 8773 Lumiracoxib 400 mg daily for 1 year Ibuprofen 800 mg t.i.d. No CV increase
EDGE* OA 7111 Etoricoxib 90 mg daily
for up to 16 months
Diclofenac 75 mg b.i.d. No CV increase
)Background !325 mg daily permitted.
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bowel. In patients receiving aspirin prophylaxis for AMI and
stroke prevention, the use of ibuprofen has been shown to
interfere with aspirin-binding to platelets, which could negate
the aspirin-protective effect on CV risk. Such interference
has been shown not to occur with low-dose celecoxib,
rofecoxib, and valdecoxib. Although diclofenac does not
interfere with aspirin prophylaxis, this agent has been
suggestively associated with increased CV risk12. Naproxen,
considered to have low CV risk when used in full doses, as
noted earlier, has also been shown to interfere with the
effect of aspirin on platelet COX-1 activity and function17.
Further complicating the issue is the observation that
sudden cessation of long-term therapy with non-selective
NSAIDs is associated with an increased risk of CV events
within 30 days post-discontinuation of these agents,
particularly in patients with rheumatoid arthritis or systemic
lupus erythematousus18. This may be the result of a re-
bound effect from platelet inhibition, as well as a decreased
effect of the NSAIDs on CV inﬂammatory processes.
Individualizing therapy for each patient, carefully weigh-
ing risks and beneﬁts, is essential. The uncertainty of CV
risk potential for non-selective as well as COX-2 selective
NSAIDs adds further complexity to therapeutic decision-
making. Important in such therapeutic considerations is the
recommendation by the FDA that, with a class effect of
NSAIDs on CV risks as a baseline, other factors must be
considered in determining the overall risk vs beneﬁt proﬁle
for individual drugs within a class16. Factors to be
considered include demonstrated beneﬁt of a given drug
over other drugs in the class related to effectiveness, as
well as differences in toxicity, making it important to
maintain a range of options in the NSAIDs class from
which physicians and patients may choose.
As with any medication, use of the lowest dose for the
shortest period of time that brings signiﬁcant relief is always
a good tenet. Intermittent use of both coxibs and non-
selective NSAIDs is likely to be associated with decreased
toxicity. Appropriate prospective randomized clinical trials to
further deﬁne evidence for or against CV risk with both
coxibs and non-selective NSAIDs are in order. Such studies
are, unfortunately, difﬁcult to design ethically since one
would be most interested in carrying out these investigations
in high CV risk patients. It is essential that we continue to
review very complicated data in scientiﬁc fashion and with
reasoned, appropriate media communications. There are
few absolute algorithms in the use of coxibs and NSAIDs;
the availability of both groups of agents provides the
practicing physician with important therapeutic alternatives.
Fortunately, similar to the initial responses to ﬁndings
related to postmenopausal hormone replacement, the
pendulum is swinging back to a more even arc, allowing
the potential for physicians and patients to use agents of
value with maximal efﬁcacy and maximal safety.
References
1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-
Vargas R, Davis B, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis. VIGOR Study
Group. N Engl J Med 2000;343:1520e8.
2. White WB, Faich G, Whelton A, Maurath C, Ridge NJ,
Verburg KM, et al. Comparison of thromboembolic
events in patients treated with celecoxib, a cyclo-
oxygenase-2 speciﬁc inhibitor, versus ibuprofen or
diclofenac. Am J Cardiol 2002;49:425e30.3. BresalierRS,SandlerRS,QuanH,BologneseJA,OxeniusB,
Horgan K, et al. Cardiovascular events associated
with rofecoxib in a colorectal adenoma chemopreven-
tion trial. N Engl J Med 2005;352:1092e102.
4. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J,
Fowler R, Finn P, et al. Cardiovascular risk associated
with celecoxib in a clinical trial for colorectal adenoma
prevention. N Engl J Med 2005;352:1071e80.
5. Witter J. (FDA)COX-2CVsafetye celecoxib. http://www.
fda.gov/ohrms/dockets/ac/05/slides/2005-4090s1.htm.
6. Farkouh ME, Kirshner H, Harrington RA, Ruland S,
Verheugt FW, Schnitzer TJ, et al. Comparison of
lumiracoxib with naproxen and ibuprofen in the
Therapeutic Arthritis Research and Gastrointestinal
Event Trial (TARGET), cardiovascular outcomes:
randomized controlled trial. Lancet 2004;364:675e84.
7. Baum LM. (FDA) Presentation by Bayer HealthCare
and Hoffman-LaRoche, Inc. http://www.fda.gov/ohrms/
dockets/ac/05/slides/2005-4090s1.htm.
8. Nussmeier NA, Whelton AA, Brown MT, Langford RM,
Hoeft A, Parlow JL, et al. Complications of the COX-2
inhibitors parecoxib and valdecoxib after cardiac
surgery. N Engl J Med 2005;352:1081e91.
9. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston
RP, Snabes MC, et al. Multicenter Study of Peri-
operative Ischemia (McSPI) Research Group; Ische-
mia Research and Education Foundation (IREF)
Investigators. Efﬁcacy and safety of the cyclooxyge-
nase 2 inhibitors parecoxib and valdecoxib in patients
undergoing coronary artery bypass surgery. J Thorac
Cardiovasc Surg 2003;125:1481e92.
10. SolomonDH,SchneeweissS,GlynnRJ,KiyotaY,LevinR,
Mogun H, et al. Relationship between selective cyclo-
oxygenase-2 inhibitors and acute myocardial infarction
in older adults. Circulation 2004;109:2068e73.
11. Mamdani M, Rochon P, Juurlink DN, Anderson GM,
Kopp A, Naglie G, et al. Effect of selective cycoox-
ygenase-2 inhibitors and naproxen on short-term risk
of acute myocardial infarction in the elderly. Arch
Intern Med 2003;163:481e6.
12. Graham D. (FDA) Review of epidemiologic studies on
cardiovascular risk with selected NSAIDs. Joint
meeting of the Arthritis Advisory Committee and the
Drug Safety and Risk Management Advisory Commit-
tee February 16e18, 2005. http://www.fda.gov/ohrms/
dockets/ac/05/slides/2005-4090s2.htm.
13. Fitzgerald, G. (FDA) Mechanism based adverse
cardiovascular events and speciﬁc inhibitors of
COX-2, http://www.fda.gov/ohrms/dockets/ac/05/slides/
2005-4090s1.htm.
14. GreenK,Drvota V, Vesterqvist O. Pronounced reduction
in prostacyclin synthesis in humans by acetaminophen
( paracetamol). Prostaglandins 1989;37:311e5.
15. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D,
Bresalier R, et al. A randomization trial of aspirin to




17. CaponeML,SciulliMG,Taconelli S,GranaM,Ricciotti E,
Renda G, et al. Pharmacodynamic interaction of
naproxen with low-dose aspirin in healthy subjects.
J Amer Coll Cardiology 45:1295e301.
18. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier
CR. Discontinuation of nonsteroidal anti-inﬂammatory
drug therapy and risk of acute myocardial infarction.
Arch Intern Med 2004;164(22):2472e6.
